India Potassium Clavulanate Market to grow at a steady rate During the Forecast Period
Growing occurrence of
bacterial infections is expected to drive the growth of India potassium
clavulanate market during the forecast period.
According
to TechSci Research report, “India Potassium Clavulanate Market By Composition (Single,
Combinational), By Route of Administration (Oral v/s Intravenous), By Form
(Tablet, Capsule, Syrup, Injection), By Distribution Channel (Online v/s
Offline), By Source (In-house v/s Contract Manufacturing Organizations), By
Application (Respiratory Tract Infections, Skin Infections, UTI, Otitis media,
Gynaecological infections, Bone and Joint Infections and Others), By End User
(Adult v/s Pediatric), By Company, By Region, Forecast & Opportunities,
FY2026”, the India potassium
clavulanate market is expected to grow at a steady pace during the forecast period.
This drug is a beta-lactamase inhibitor which
is commonly used in combination with other antibiotics such as amoxicillin,
cefixime, and cefpodoxime in order to fight the antibiotic resistance. Potassium clavulanate is available in both
generic and brand versions. High mortality rate associated with
community-acquired pneumonia is one of the major factors which is expected to
fuel the market growth through FY2026. However, side effects caused due to drug
consumption including diarrhea, nausea, vomiting, headache, skin rash or
itching, can restrict the market growth over the next few years. Lack of
awareness about the onset and risks of bacterial infections among the
population might act as a major impediments to the market growth in the coming
years.
TABLE 1: Newer Antibiotics Used in
Skin and Soft Tissue Infections
|
Serial
No.
|
CLASS
(Systemic)
|
COMPOUND
|
MECHANISM
OF ACTION
|
|
1.
|
Cephalosporins
|
2nd
generation Cefprozil
|
Inhibits
bacterial cell wall synthesis
|
|
2.
|
Carbapenem
|
Meropenem
|
Inhibits
bacterial cell wall synthesis by binding penicillin-binding proteins.
|
|
3.
|
Macrolides
|
Clarithromycin
|
Inhibition of
RNA-dependent protein synthesis by binding to 50S subunit of 70S ribosome.
|
|
4.
|
Fluoroquinolones
|
Levofloxacin
|
Inhibition of
bacterial DNA gyrase
|
|
5.
|
Glycopeptides
|
Dalbavancin
|
Inhibits
biosynthesis of peptidoglycans.
|
Source:
IJDVL (Indian Journal of Dermatology, Venereology and Leprology)
Browse
XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC
on " India Potassium Clavulanate Market"
https://www.techsciresearch.com/report/india-potassium-clavulanate-market/7201.html
The India potassium clavulanate market is segmented based on composition, route of administration,
form, distribution channel, source, application, end user, company,
and region. Based on source, the market can be categorized into in-house v/s
contract manufacturing organizations. The in-house segment dominated the market
until FY2020 as majority of the key market players prefer in house production
owing to the reduced dependency on suppliers. Additionally, in-house production
can provide fast and flexible response to market changes which is further
expected to contribute to the segmental growth during the forecast period.
Based on end user, the market can be fragmented into adult v/s pediatric. Adult
end user segment dominated the market until FY2020 and is expected to maintain
its dominance in the market during forecasted years as well on account of high
incidence of bacterial infections in adults.
MacLeod’s Pharmaceuticals Ltd.., Hetero
Healthcare Ltd., HLL Lifecare Ltd., Novartis India Ltd. (Sandoz), Modi Mundipharma Ltd., Ikon
Remedies Pvt. Ltd., Glenmark Pharmaceuticals Ltd., Elkos Healthcare Pvt. Ltd.,
Lupin Laboratories Ltd., Zee Laboratories Ltd. and others are
some of the leading players operating in India potassium clavulanate market. Companies operating in the market are using organic
strategies such as product launches, mergers and acquisitions and research
collaborations to boost their share and increase their geographic reach.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7201
Customers can also request for 10% free customization on
this report.
“India potassium clavulanate market is expected
to witness growth in the next 5 years which can be attributed to the popularity
of this drug among the individuals for treatment of pyelonephritis caused by
gram-positive bacteria. In addition to this, increased count of skin and tissue
infections amongst population including cellulitis, animal bites, severe dental
abscess, etc. is further expected to create lucrative opportunities for the
market growth of India potassium clavulanate market over the next five years. Rising
percentage of geriatrics in the country is forecasted to aid the growth of potassium
clavulanate market over the forthcoming years.” said Mr. Karan Chechi, Research Director with
TechSci Research, a research based India management consulting firm.
“India Potassium Clavulanate Market By Composition
(Single, Combinational), By Route of Administration (Oral v/s Intravenous), By
Form (Tablet, Capsule, Syrup, Injection), By Distribution Channel (Online v/s
Offline), By Source (In-house v/s Contract Manufacturing Organizations), By
Application (Respiratory Tract Infections, Skin Infections, UTI, Otitis media,
Gynaecological infections, Bone and Joint Infections and Others), By End User
(Adult v/s Pediatric), By Company, By Region, Forecast & Opportunities,
FY2026”, has
evaluated the future growth potential of India potassium clavulanate market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in India potassium clavulanate market.
Contact
Mr. Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email:
[email protected]